Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human GBA Anticorps:
anti-Mouse (Murine) GBA Anticorps:
anti-Rat (Rattus) GBA Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Monoclonal GBA Primary Antibody pour IF, IHC (p) - ABIN561009
Campeau, Rafei, Boivin, Sun, Grabowski, Galipeau: Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. dans Blood 2009
Show all 5 Pubmed References
Human Polyclonal GBA Primary Antibody pour ICC, IF - ABIN442242
Zancan, Bellesso, Costa, Salvalaio, Stroppiano, Hammond, Argenton, Filocamo, Moro: Glucocerebrosidase deficiency in zebrafish affects primary bone ossification through increased oxidative stress and reduced Wnt/β-catenin signaling. dans Human molecular genetics 2015
Show all 2 Pubmed References
Human Monoclonal GBA Primary Antibody pour IHC, WB - ABIN2721971
Massaro, Mattar, Wong, Sirka, Buckley, Herbert, Karlsson, Perocheau, Burke, Heales, Richard-Londt, Brandner, Huebecker, Priestman, Platt, Mills, Biswas, Cooper, Chan, Cheng, Waddington, Rahim: Fetal gene therapy for neurodegenerative disease of infants. dans Nature medicine 2018
In recently diagnosed Parkinson's disease patients, GCase activity was significantly reduced in monocytes, but not lymphocytes, compared to controls, even when GBA1 mutation carriers were excluded. Monocyte GCase activity correlated with plasma ceramide levels in the Parkinson's disease patients.
The p.Trp378Gly mutation is the first French-Canadian founder GBA mutation to be described, which leads to synucleinopathies and to GD type 1 when in compound heterozygosity with p.Asn370Ser
This study demonstrated that Survival of patients with Parkinson's disease does not seem to be related to GBA status.
Study confirms the influence of glucocerebrosidase mutations on the age of onset, disease severity and motor phenotype in patients with Parkinson's disease.
A total of 12.0% of patients with Parkinson's disease carried a GBA variant, and nearly half (22/53) of them progressed to dementia during follow-up. Carriers of deleterious GBA mutations or polymorphisms progressed to dementia more rapidly than noncarriers.
GBA mutation may not be so common in Indian patients with Parkinson disease as compared to the other ethnic populations.
This study showed that Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene.
This study demonstrated that the Lysosphingolipid accumulations in parkinson's disease patients who bear glucocerebrosidase 1 mutations suggest that substrate reduction therapy might be viewed as a possible strategy for glucocerebrosidase 1-parkinson's disease treatment
Study reports four novel and 29 known mutations identified in the GBA1 gene in one-hundred Gaucher patients. The given study establishes p.Leu483Pro as the most prevalent mutation in the Indian patients with type 1 Gaucher disease.
This study investigated 22 unrelated Chinese patients, including their clinical presentations, plasma psychosine levels and beta-galactocerebrosidase gene mutations. We found the late-onset form of Krabbe disease (KD) present in 82% of the patients in our study, which was more prevalent than in patients from other populations.
Using skin-derived induced pluripotent stem cells of PD patients with GBA mutations and controls, we observed a significant GBA up-regulation during dopaminergic differentiation, paralleled by down-regulation of miR-22-3p. Our results describe the first microRNA controlling GBA and suggest that the GBAP1 non-coding RNA functions as a GBA ceRNA
The study reports novel and known variants identified in the GBA gene in seven adult Indian patients with Gaucher disease.
we identified patients found to carry more than one GBA1 mutation on the same allele. It is essential to examine the entire GBA1 gene in order to establish an accurate genotype. Missing the second mutation can complicate genotype/phenotype studies and result in improper genetic counseling
The p.L216I mutation is a novel glucocerebrosidase (GBA)mutation, which we identified in two Han Chinese patients with Parkinson disease. The patients exhibited similar characteristics, which differed from those seen in patients with other GBA mutations.
We demonstrated that deficiency of GCase(GBA1) leads to a reduction of C18-ceramide species and altered intracellular localization of Rab8a, a small GTPase implicated in secretory autophagy, that contributed to impaired secretion of a-synuclein and accumulation of intracellular a-synuclein.
Loss of GBA activity is associated with Gaucher Disease.
Chinese type 2 Gaucher disease patients have a similar phenotype to other ethnic groups and have a high prevalence of the c.1448T>C (p.Leu483Pro) mutation and recombination alleles.
The binding affinities of a-1-C-alkyl 1,4-dideoxy-1,4-imino-d-arabinitol (DAB) derivatives, which act as pharmacological chaperones for beta-glucocerebrosidase, abruptly increased upon elongation of their alkyl chain. In this study, the primary causes of such an increase in binding affinity were analyzed using proteinligand docking and molecular dynamics simulations.
The POLG1 CAG repeat length variation and the GBA p.L444P variant are associated with Parkinson's disease in the Finnish population
that GBA variant E326K may fully account for the primary association signal observed at chromosome 1q22 in previous GWAS of PD
Results describe the characterization of a beta-glucosidase homolog from Arabidopsis thaliana.
The results of this study indicated that GBA1 deficiency due to D409H GBA1 mutation that contributes to alpha-synuclein accumulation exacerbates neuronal vulnerability in neurodegenerative processes triggered by A53T alpha-synuclein expression in vivo
these results provide for the first time evidence that a decrease of GCase or overexpression of mutant GCase in a chronic in vivo setting can affect ASYN secretion. Such effects may mediate enhanced propagation of ASYN, driving pathology in GBA-associated Parkinson's disease
Thus, while the underlying mechanism is not clear, this model shows that gba deficiency impacts the age of onset and disease duration in aged SNCA(A53T) mice, providing a valuable resource to identify modifiers, pathways and possible moonlighting roles of glucocerebrosidase in Parkinson pathogenesis.
The data support the contention that prolonged antagonism of glucosylceramide synthase (GCS)in the central nervous system (CNS)can affect alpha-synuclein processing and improve behavioral outcomes. Hence, inhibition of GCS represents a disease-modifying therapeutic strategy for GBA-related synucleinopathies and conceivably for certain forms of sporadic disease
These results indicate that Gba1 deficiency enhances neuronal vulnerability to neurodegenerative processes triggered by increased alpha-synuclein expression.
This study demonstrated that the gba1 deficiency mice showed gene regulation expression of the type I interferon.
Rab7 accumulated in GCase deficient cells, supporting the notion that lysosomal recycling is impaired. Since recombinant GCase can reverse ALR impairment, we anticipate that strategies to restore GCase activity in the brains of both sporadic patients with PD and those with GBA1 mutations will improve autophagy lysosomal pathway, preventing the accumulation of a-synuclein and spread of pathology.
In LIMP-2-deficient brains a significant reduction in GC activity led to lipid storage, disturbed autophagic/lysosomal function, and alpha-synuclein accumulation.
heterozygosity for a Gaucher disease-associated mutation in glucocerebrosidase interferes with alpha-synuclein degradation and contributes to its accumulation
Data indicate that ABC transporter A family member 12 knockout (Abca12(-/-)) epidermis had 5-fold more beta-glucocerebrosidase (GCase) protein, and a 5-fold increase in GCase activity.
These results demonstrate, for the first time, a novel function of GBA1 as a beta-ChlGlc-synthesizing enzyme.
Substrate compositional variation with tissue/region and Gba1 mutations in mouse models--implications for Gaucher disease.
GBA1 and GBA2 activities had characteristic differences between the studied fibroblast, liver and brain samples.
results not only point to a fundamental role for GBA in immune regulation but also suggest that GBA mutations in GD may cause widespread immune dysregulation through the accumulation of substrates
This study suggested that several leads connecting GBA1 mutations with alpha-synuclein misprocessing have emerged as potential targets for the treatment of GBA1-related synucleinopathies.
IFG stabilizes GCase in tissues and serum and can reduce visceral substrates in vivo.
Mutations in GBA1 can cause Parkinson disease-like alpha-synuclein pathology; rescuing brain glucocerebrosidase activity might represent a therapeutic strategy for GBA1-associated synucleinopathies.
evidence for the involvement of deletion of the GBA1 gene in multiple cell lineages in nonneuronopathic type 1 Gaucher disease
The saposin C deficient mice backcrossed to point mutated GCase mimics the central nervous system phenotype and biochemistry of some type 3 (neuronopathic) variants of Gaucher disease.
isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase
genetic analysis and mapping of the porcine glucocerebrosidase (GBA) gene
This gene encodes a lysosomal membrane protein that cleaves the beta-glucosidic linkage of glycosylceramide, an intermediate in glycolipid metabolism. Mutations in this gene cause Gaucher disease, a lysosomal storage disease characterized by an accumulation of glucocerebrosides. A related pseudogene is approximately 12 kb downstream of this gene on chromosome 1. Alternative splicing results in multiple transcript variants.
, acid beta-glucosidase
, lysosomal glucocerebrosidase
, acid beta glucosidase
, glucosidase, beta; acid
, glucosidase, beta, acid
, glucosidase, beta; acid (includes glucosylceramidase)